EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
Back to course
Pdf Summary
Asset Subtitle
Joshua Sabari
Meta Tag
Speaker Joshua Sabari
Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy
Keywords
real-world overall survival
EGFR-mutant NSCLC
osimertinib
FLAURA trial
US oncology databases
brain metastases
TP53 mutation
L858R mutation
personalized medicine
treatment continuation
Powered By